Prokineticin 2 Is a Hypothalamic Neuropeptide That Potently Inhibits Food Intake
- James V. Gardiner1,
- Attia Bataveljic1,
- Neekhil A. Patel1,
- Gavin A. Bewick1,
- Debabrata Roy1,
- Daniel Campbell1,
- Hannah C. Greenwood1,
- Kevin G. Murphy1,
- Saira Hameed1,
- Preeti H. Jethwa2,
- Francis J.P. Ebling2,
- Steven P. Vickers3,
- Sharon Cheetham3,
- Mohammad A. Ghatei1,
- Stephen R. Bloom1 and
- Waljit S. Dhillo1
- 1Department of Investigative Medicine, Imperial College London, London, U.K.;
- 2School of Biomedical Sciences, University of Nottingham, Nottingham, U.K.;
- 3RenaSci Consultancy Ltd, Nottingham, U.K.
- Corresponding author: Stephen R. Bloom, s.bloom{at}imperial.ac.uk.
-
J.V.G., A.B., and N.A.P. contributed equally to this study.
Abstract
OBJECTIVE Prokineticin 2 (PK2) is a hypothalamic neuropeptide expressed in central nervous system areas known to be involved in food intake. We therefore hypothesized that PK2 plays a role in energy homeostasis.
RESEARCH DESIGN AND METHODS We investigated the effect of nutritional status on hypothalamic PK2 expression and effects of PK2 on the regulation of food intake by intracerebroventricular (ICV) injection of PK2 and anti-PK2 antibody. Subsequently, we investigated the potential mechanism of action by determining sites of neuronal activation after ICV injection of PK2, the hypothalamic site of action of PK2, and interaction between PK2 and other hypothalamic neuropeptides regulating energy homeostasis. To investigate PK2's potential as a therapeutic target, we investigated the effect of chronic administration in lean and obese mice.
RESULTS Hypothalamic PK2 expression was reduced by fasting. ICV administration of PK2 to rats potently inhibited food intake, whereas anti-PK2 antibody increased food intake, suggesting that PK2 is an anorectic neuropeptide. ICV administration of PK2 increased c-fos expression in proopiomelanocortin neurons of the arcuate nucleus (ARC) of the hypothalamus. In keeping with this, PK2 administration into the ARC reduced food intake and PK2 increased the release of α-melanocyte–stimulating hormone (α-MSH) from ex vivo hypothalamic explants. In addition, ICV coadministration of the α-MSH antagonist agouti-related peptide blocked the anorexigenic effects of PK2. Chronic peripheral administration of PK2 reduced food and body weight in lean and obese mice.
CONCLUSIONS This is the first report showing that PK2 has a role in appetite regulation and its anorectic effect is mediated partly via the melanocortin system.
Footnotes
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Received August 11, 2009.
- Accepted November 6, 2009.
- © 2010 by the American Diabetes Association.











